← ranked final candidates

#15 INFU — InfuSystem Holdings, Inc

A2_VCP_NEAR_PIVOT | as of 2026-09-15 | automated relative priority, not a published Minervini point formula

Relative priority42.11
RS rating83.40
Fundamental strength10.53
VCP score90.48
Pivot distance1.68%
AV confirmation100.00%complete
Technical chart for INFU

Trend Template

price_above_sma150_and_sma200PASS
sma150_above_sma200PASS
sma200_rising_1mPASS
sma50_above_sma150_and_sma200PASS
price_above_sma50PASS
price_at_least_30pct_above_52w_lowPASS
price_within_25pct_of_52w_highPASS
rs_rating_at_least_70PASS

Trend Template metrics

close12.26
sma5011.02
sma1509.89
sma2009.60
sma200_1m_ago9.36
pct_above_52w_low68.18
pct_below_52w_high5.47
rs_rating83.40

VCP conditions

coherent_contraction_sequencePASS
enough_contractionsPASS
successive_ranges_inside_firstPASS
successive_depths_contractingPASS
final_contraction_tightPASS
base_depth_okPASS
resistance_area_tightPASS
volume_dryupFAIL
atr_contractingPASS
price_tightPASS
near_pivotPASS

VCP metrics

num_contractions2.00
contraction_depths_pct[9.1, 5.29]
depth_ratios_vs_prior[0.581]
target_depth_ratio_roughly_half0.50
max_allowed_depth_ratio0.80
base_high12.97
base_low11.79
base_depth_pct9.10
base_duration_weeks5.90
resistance_spread_pct3.86
volume_dryup_ratio_10d_vs_50d0.83
atr_pct_recent2.63
atr_pct_prior4.83
atr_contraction_ratio0.54
tight_10d_range_pct5.68
raw_contraction_count9.00
raw_depths_pct[11.32, 12.55, 24.86, 14.55, 7.7, 15.79, 11.2, 9.1, 5.29]
final_trough_age_bars5.00
selection_reasoncoherent_current_sequence
pivot_price12.47
distance_to_pivot_pct1.68
vcp_score_pct90.48
is_vcp_candidatePASS
breakout_on_volumeFAIL

Price / volume

return_1m_pct-0.08
return_3m_pct39.32
return_6m_pct28.11
return_12m_pct22.72
weighted_12m_momentum13.34
range_10d_pct5.68
range_20d_pct6.02
avg_volume_50d138,492
dollar_volume_50d1.70M
up_down_volume_ratio_50d1.33
accumulation_days_20d1.00
distribution_days_20d1.00

Fundamental overlay criteria

eps_growth_minimumPASS
sales_growth_positive_or_betterPASS
core_data_coveragePASS
eps_acceleratingFAIL
sales_acceleratingPASS
gross_margin_improvingPASS
operating_margin_improvingPASS

Minervini-oriented SEC fundamentals

eps_growth_yoy_pct25.00
eps_previous_q_yoy_growth_pct600.00
eps_acceleration_pts-575.00
eps_annual_growth_pct181.82
eps_cagr_3y_pct—
sales_growth_yoy_pct2.59
sales_previous_q_yoy_growth_pct-2.97
sales_acceleration_pts5.56
sales_annual_growth_pct6.36
sales_cagr_3y_pct9.28
gross_margin_pct57.98
operating_margin_pct11.24
pretax_margin_pct10.48
net_margin_pct8.75
gross_margin_yoy_change_pts2.77
operating_margin_yoy_change_pts0.75
roe_latest_fy_pct11.54
current_ratio2.50
debt_to_equity_pct34.53
cash_to_debt0.05
shares_outstanding—
adjusted_eps_growth_yoy_pct—
earnings_surprise_pct—
eps_estimate_revision_30d_pct—
analyst_count—
institutional_ownership_pct—
institutional_qoq_change_pct—
management_guidance_revision_pct—

SEC data quality

core_coverage_pct90.00
missing_core_metrics["shares_outstanding"]
selected_sec_tags{"accounts_payable": "us-gaap:AccountsPayableCurrent", "accounts_receivable": "us-gaap:AccountsReceivableNetCurrent", "capex": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "cash": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "cost_of_revenue": "us-gaap:CostOfGoodsAndServicesSold", "current_assets": "us-gaap:AssetsCurrent", "current_liabilities": "us-gaap:LiabilitiesCurrent", "dividends_paid": null, "eps_basic": "us-gaap:EarningsPerShareBasic", "eps_diluted": "us-gaap:EarningsPerShareDiluted", "equity": "us-gaap:StockholdersEquity", "gross_profit": "us-gaap:GrossProfit", "inventory": "us-gaap:InventoryNet", "long_term_debt": "us-gaap:LongTermDebtNoncurrent", "long_term_debt_current": "us-gaap:LongTermDebtCurrent", "net_income": "us-gaap:NetIncomeLoss", "operating_cash_flow": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "operating_income": "us-gaap:OperatingIncomeLoss", "pretax_income": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "r_and_d": null, "revenue": "us-gaap:Revenues", "sga": "us-gaap:GeneralAndAdministrativeExpense", "share_repurchases": "us-gaap:PaymentsForRepurchaseOfCommonStock", "shares_outstanding": "dei:EntityCommonStockSharesOutstanding", "short_term_debt": null, "short_term_investments": null, "stock_based_comp": "us-gaap:ShareBasedCompensation", "total_assets": "us-gaap:Assets", "total_liabilities": "us-gaap:Liabilities", "weighted_avg_diluted_shares": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding"}
unavailable_canonical_concepts["dividends_paid", "r_and_d", "short_term_debt", "short_term_investments"]
warnings["Standalone Q4 income/EPS can be absent because 10-K statements are annual.", "Company-specific extension tags are not returned by CompanyFacts.", "Non-GAAP EPS, guidance, 13F ownership, Form 4 activity, and analyst estimates are separate modules."]

Reporting periods

latest_quarter_end2026-06-30
latest_quarter_filed2026-08-04
latest_fiscal_year_end2025-12-31
latest_balance_sheet_end2026-06-30

Company metadata

symbolINFU
cik1.34M
company_nameInfuSystem Holdings, Inc
exchange—
sic3,841
sic_descriptionSurgical & Medical Instruments & Apparatus
fiscal_year_end1,231
as_of2026-09-15
sourceSEC EDGAR CompanyFacts + Submissions

Alpha Vantage enrichment

latest_reported_date2026-08-04
latest_reported_eps0.15
latest_estimated_eps0.12
latest_earnings_surprise_pct25.00
avg_earnings_surprise_4q_pct83.63
positive_earnings_surprises_4q4.00
earnings_surprise_quarters_available4.00
reported_eps_yoy_growth_pct0.00
estimate_period2027-12-31
analyst_count_eps—
analyst_count_revenue—
eps_estimate_avg—
revenue_estimate_avg—
estimate_revision.eps_estimate_revision_up_trailing_7_days0.00
estimate_revision.eps_estimate_revision_up_trailing_30_days0.00
estimate_revision.eps_estimate_revision_down_trailing_30_days0.00
eps_revision_up_30d0.00
eps_revision_down_30d0.00
eps_revision_net_up_30d0.00
institutional.total_institutional_holders124.00
institutional.total_institutional_shares15.50M
institutional.holders_with_increased_holdings59.00
institutional.holders_with_decreased_holdings46.00
institutional.holders_with_unchanged_holdings19.00
institutional_holder_rows124.00
institutional_total_shares15.50M
endpoints_returned["EARNINGS", "EARNINGS_ESTIMATES", "INSTITUTIONAL_HOLDINGS"]

Alpha Vantage confirmation screen

latest_earnings_surprise_positivePASS
average_4q_earnings_surprise_positivePASS
positive_surprise_quartersPASS
analyst_coverage_present—
eps_revision_breadth_nonnegative_30dPASS
institutional_sponsorship_presentPASS

Alpha Vantage screen summary

statuscomplete
confirmation_score_pct100.00
available_criteria5.00
noteInformational post-Exp0 confirmation only; not part of validated Exp0 selection/ranking.

Alpha Vantage endpoint status

EARNINGScache_available
EARNINGS_ESTIMATEScache_available
INSTITUTIONAL_HOLDINGScache_available

Accepted VCP contractions

peak_datepeak_pricetrough_datetrough_pricedepth_pctdepth_ratio_vs_priorbars
2026-08-0512.972026-08-2611.799.10—15.00
2026-09-0312.472026-09-0811.815.290.582.00

Recent SEC filings

formfiling_dateaccession_numberprimary_document
10-Q2026-08-040001628280-26-052462infu-20260630.htm
8-K2026-08-040001628280-26-052123infu-20260804.htm
8-K2026-08-040001628280-26-052112infu-20260804.htm
8-K2026-07-280001628280-26-049931infu-20260728.htm
8-K2026-05-180001628280-26-035967infu-20260512.htm
8-K2026-05-140001628280-26-034839infu-20260511.htm
8-K2026-05-120001628280-26-034217infu-20260511.htm
10-Q2026-05-080001628280-26-032737infu-20260331.htm
8-K2026-05-070001628280-26-031649infu-20260507.htm
8-K2026-04-300001628280-26-028564infu-20260430.htm
8-K2026-03-190001628280-26-019649infu-20260313.htm
8-K2026-03-160001628280-26-018216infu-20260316.htm

SEPA factors not covered by SEC + Yahoo

These remain manual or require another provider/module and are deliberately not guessed: